Thomas A Hope
Overview
Explore the profile of Thomas A Hope including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
232
Citations
5144
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Murthy V, Ludwig V, Gafita A, Hope T, Calais J
J Nucl Med
. 2025 Feb;
PMID: 40015925
Prostate-specific membrane antigen (PSMA) PET is a well-established imaging tool for the evaluation of primary and recurrent prostate cancer (PCa). Lu PSMA-targeted radiopharmaceutical therapy (RPT) enables direct delivery of β-radiation...
2.
Raychaudhuri R, Tuchayi A, Low S, Arafa A, Graham L, Gulati R, et al.
Eur Urol Oncol
. 2025 Feb;
PMID: 39920014
Background And Objective: The prostate-specific membrane antigen (PSMA) radioligand Lu-PSMA-617 (LuPSMA) is approved for treatment of metastatic castration-resistant prostate cancer (mCRPC). PARP inhibitors (PARPi) are approved for patients with mCRPC...
3.
Lindenberg L, Hope T, Lin F, Rowe S, Pucar D, Gilbert N, et al.
J Nucl Med
. 2025 Feb;
66(3):359-365.
PMID: 39915126
Prostate-specific membrane antigen (PSMA) is highly expressed in most prostate cancers (PCs). PET and CT imaging studies using Ga-labeled PSMA ligands demonstrated the specific localization of Ga in PC lesions...
4.
Unterrainer L, Hope T, Fendler W, Grogan T, Ndlovu H, Armstrong W, et al.
J Nucl Med
. 2025 Jan;
66(1):54-60.
PMID: 39753363
High-volume disease (HVD) and low-volume disease (LVD) definitions in metastatic hormone-sensitive prostate cancer (mHSPC) patients are based on conventional imaging (CI) (CT/MRI with bone scan [BS]) according to CHAARTED criteria....
5.
Bryce A, Agarwal N, Beltran H, Hussain M, Sartor O, Shore N, et al.
Cancer
. 2024 Dec;
131(1):e35612.
PMID: 39616467
Current US clinical practice guidelines for advanced prostate cancer management contain recommendations based on high-level evidence from randomized controlled trials; however, these guidelines do not address the nuanced clinical questions...
6.
Hope T, Calais J, Goenka A, Haberkorn U, Konijnenberg M, McConathy J, et al.
J Nucl Med
. 2024 Nov;
66(1):26-33.
PMID: 39572227
No abstract available.
7.
Armstrong W, Kishan A, Booker K, Grogan T, Elashoff D, Lam E, et al.
Eur Urol
. 2024 Nov;
87(1):97-99.
PMID: 39521695
No abstract available.
8.
Kong G, Noe G, Chiang C, Herrmann K, Hope T, Michael M
J Neuroendocrinol
. 2024 Nov;
:e13461.
PMID: 39520276
Peptide receptor radionuclide therapy (PRRT) is an effective treatment for both oncological and hormone control and is a widely accepted standard of care treatment for patients with neuroendocrine neoplasms (NEN)....
9.
Sollini M, Calais J, Chiti A, Emmett L, Fanti S, Fendler W, et al.
Eur Urol
. 2024 Oct;
87(2):125-139.
PMID: 39428326
Background And Objective: This review aims to provide an overview of novel diagnostic and therapeutic radiopharmaceuticals tested recently or used currently in genitourinary cancers within prospective phase 1-2 clinical trials,...
10.
Gillessen S, Turco F, Davis I, Efstathiou J, Fizazi K, James N, et al.
Eur Urol
. 2024 Oct;
87(2):157-216.
PMID: 39394013
Background And Objective: Innovations have improved outcomes in advanced prostate cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that greatly impact daily practice. The...